Text Box: PUBLICATIONS 

 

 

 


PEER REVIEWED ARTICLES

 

1.                  Belch, JJF, Lowe GDO, Pollock JG, Forbes CD, Prentice CRM. Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery. Thrombosis and Haemostasis 1980; 42 (5): 1429-1433.

 

2.                  Belch, JJF, Douglas J, Lowe GDO, Forbes CD. Effect of des-amino-D-arginine vasopressin (DDAVP) infusion on circulating platelet aggregates in patients with Haemophilia A. Thrombosis and Haemostasis 1980; 44: 168.

 

3.                  Lowe GDO, Lowe JM, Drummond MM, Belch, JJF, Reith S, Kesson CM, Wylie A, Foulds WS, Forbes CD, MacCuish AC, Manderson WG. Blood viscosity in young male diabetics with and without retinopathy. Diabetologia 1980; 18 (5): 359-363.

 

4.                  Drummond MM, Lowe GDO, Belch, JJF, Barbenel JC, Forbes CD. An assessment of red cell deformability. Journal of Clinical Pathology 1980; 33 (4): 373-376.

 

5.                  Lowe GDO, Belch, JJF, Forbes CD, Prentice CRM. The contribution of cigarette smoking to blood viscosity in intermittent claudication. Thrombosis and Haemostasis 1980; 44: 69.

 

6.                  Belch, JJF, Lowe GDO, Ward AG, Forbes CD, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal 1981; 26 (2): 115-117.

 

7.                  Belch, JJF, Lowe GDO, Drummond MM, Forbes CD, Prentice CRM. Prostacyclin reduces red cell deformability.  Thrombosis and Haemostasis 1981: 45 (2); 189.

 

8.                  Beattie J, Murphy A, Willoughby M, Belch, JJF. Prostacyclin infusion in haemolytic uraemic syndrome of children. British Medical Journal 1981; 283 (6289): 470.

 

9.                  Lowe GDO, McArdle BM, Osbourne DH, Smith A, Belch, JJF, Carter DC, Forbes CD, Prentice CRM. Clinical and laboratory variables in prediction of venous thrombosis after elective gastro-intestinal surgery. Thrombosis and Haemostasis 1981; 46: 17.

 

10.             Belch, JJF, McMillan N, Capell HA, Forbes CD.  Differential diagnosis in ten patients with arthritis and swollen calves. British Medical Journal 1981; 282; (6268): 949.

 

11.             Belch, JJF, Newman P, Drury JK, Capell HA, Leiberman P, James WB, Forbes CD, Prentice CRM. Successful treatment of Raynaud's syndrome with prostacyclin. Thrombosis and Haemostasis 1981; 45 (3): 255-256.

 

12.             Belch, JJF, Small M, McKenzie F, McIntyre E, Forbes CD, Prentice CRM. DDAVP stimulates prostacyclin production. Thrombosis and Haemostasis 1982; 47 (2): 122-123.

 

13.             Douglas J, Shah M, Lowe GDO, Belch, JJF, Forbes CD, Prentice CRM. Plasma fibrinopeptide A and β thromboglobulin in pre-eclampsia and essential hypertension in pregnancy. Thrombosis and Haemostasis 1982; 47 (1): 54-55.

 

14.             Belch, JJF, Meek D, Lowe GDO, Forbes CD, Prentice CRM. Subcutaneous ancrod in the prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery. Thrombosis Research 1982; 25 (1-2): 23-31.

 

15.             Lowe GDO, Belch, JJF, Regan K, Forbes CD, Prentice CRM. Sustained increase in Anti-Xa activity by low-dose heparin in medical patients. Thrombosis and Haemostasis 1982; 47 (3): 296.

 

16.             Walker JJ, Belch, JJF, Erwin L, McLaren M, Lang G, Forbes CD, Prentice CRM, Calder AA. Labetalol and platelet function in pre-eclampsia. Lancet 1982; 2 (8292): 279.

 

17.             Small M, Rose PE, McMillan N, Belch, JJF, Rolfe EB, Lowe GDO, Stuart J, Forbes CD. Haemophilia and the kidney. British Medical Journal 1982; 285 (6355): 1609-1611.

 

18.             Small M, Stevens MM, Freeman PA, Lowe GDO, Belch, JJF, Forbes CD, Prentice CRM. Total knee arthroplasty in haemophilic arthritis.  Journal of Bone and Joint Surgery 1983; 65 (2): 163-165.

 

19.             Belch, JJF, Cormie J, Newman P, McLaren M, Barbenel J, Capell HA, Leiberman P, Forbes CD, Prentice CRM. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: A double blind trial. British Journal of Clinical Pharmacology 1983; 15 (1): 113-116.

 

20.             Belch, JJF, McKay A, McArdle B, Lowe GDO, Pollock JG, Leiberman P, Forbes CD, Prentice CRM. A double blind study of the effect of prostacyclin infusion in severe peripheral vascular disease. Lancet 1983; 1 (8320): 315-317.

 

21.             Belch, JJF, Newman P, Drury JK, McKenzie F, Leiberman P, Capell HA, Forbes CD, Prentice CRM. Intermittent prostacyclin infusions in patients with Raynaud's syndrome: a double blind trial. Lancet 1983; 1 (8320): 313-315.

 

22.             Saniabadi AR, Lowe GDO, Belch, JJF, Forbes CD, Prentice CRM, Barbenel JC. The novel effect of a new prostacyclin analogue ZK36-374 on the aggregation of human platelets in whole blood. Thrombosis and Haemostasis 1983; 50 (3): 718-721.

 

23.             Belch, JJF, McArdle B, Forbes CD, McKay A, Lowe GDO, Prentice CRM. Epoprostenol et arteriopathie severe. Journal International de Medicin 1983; 44: 25-28.

 

24.             Greer IA, Walker JJ, McLaren M, Belch JJF, Calder AA, Forbes CD. Alternative mechanisms for the hypotensive effects of adrenergic blockade. British Medical Journal 1983; 287 (6404): 1551.

 

25.             Belch, JJF, Greer I, McLaren M, Walker J, Forbes CD. Prostacyclin metabolite assay. Lancet 1983; 2 (8365): 1504.

 

26.             Belch, JJF, McArdle B, Burns P, Lowe GDO, Forbes CD. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorrheology in habitual smokers. Thrombosis Research 1984; 51 (1): 6-8.

 

27.             Prowse CV, Farrugia A, Boulton FE, Tucker J, Ludlam CA, McLaren M, Belch, JJF, Prentice CRM, Dawes J, MacGregor IR. A comparative study using immunological and biological assays of the haemostatic responses to DDAVP infusion, venous occlusion and exercise in normal men. Thrombosis and Haemostasis 1984; 51 (1): 110-114.

 

28.             Belch, JJF, Greer IA, McLaren M, Saniabadi AR, Miller S, Sturrock RD, Forbes CD. The effects of intravenous infusion of ZK36374, a synthetic prostacyclin derivative, on normal volunteers. Prostaglandins 1984; 28 (1): 67-77.

 

29.             Steven MM, Teh LG, Teh LS, Pullar T, Belch, JJF, Lewis D, Parker J, Zoma AA. Can the number of antinuclear antibody tests performed in patients with rheumatic diseases be reduced? British Medical Journal 1984; 288 (6432): 1724-1725.

 

30.             Roche P, Gijsbers K, Belch, JJF, Forbes CD. Modification of induced ischaemic pain by transcutaneous electrical nerve stimulation. Pain 1984; 20 (1): 45-52.

 

31.             Belch, JJF, McArdle B, Madhok R, McLaughlin K, Forbes CD, Sturrock RD. Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Annals of Rheumatic Diseases 1984; 43 (6): 774-779.

 

32.             Hutchinson S, Belch, JJF. Bechets disease and myocardial infarction: a case report. British Heart Journal 1984; 52 (6): 686-687.

 

33.             Saniabadi AR, Lowe GD, Belch, JJF, Barbenel JC, Forbes CD. Effect of prostacyclin (Epoprostenol) on the aggregation of human platelets in whole blood in vitro. Haemostasis 1984; 14 (6): 487-494.

 

34.             Johnston RV, Belch, JJF, Forbes CD. The effect of a nicotine containing chewing gum on the coagulation system in normal volunteers. Thrombosis Research 1984; 35 (1): 99-104.

 

35.             Greer IA, Winter JH, Gaffney D, McLoughlin K, Belch JJF, Boyd G, Forbes CD. Platelets in asthma. The Lancet 1984; 2 (8417): 1479.

 

36.             Belch, JJF, McLaren M, Anderson J, Lowe GDO, Sturrock RD, Capell HA, Forbes CD. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins, Leukotrienes and Medicine, 1985; 17 (1): 1-9.

 

37.             Belch, JJF, Madhok R, Shaw, B, Leiberman P, Forbes CD, Sturrock RD. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, as a treatment for Raynaud's phenomenon. Lancet 1985; 1 (8439): 1180-1183.

 

38.             Roche A, Gijsbers K, Belch, JJF, Forbes CD. Modification of haemophiliac haemorrhage joint pain by transcutaneous electrical nerve stimulation. Pain 1985; 21 (1): 43-48.

 

39.             Belch, JJF, Greer I, Sarfo S, Thorburn J, Prentice CRM. Prostacyclin in the treatment of severe pregnancy induced hypertension. Journal of Clinical and Experimental Hypertension, 1985; 4 (1): 75-86.

 

40.             Belch, JJF, O'Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. British Journal of Rheumatology 1985; 24 (4): 346-350.

 

41.             Belch, JJF, Shaw B, O'Dowd A, Saniabadi A, Leiberman P, Sturrock RD, Forbes CD. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thrombosis and Haemostasis 1985; 54 (2): 490-494.

 

42.             Sandilands GP, Peel MG, Froebel KS, Belch, JJF, MacSween RNM. Isolation of labile FC gamma receptors from human peripheral blood lymphocytes and production of an antiserum. Immunology 1985; 55 (1): 7-13.

 

43.             Drury J, Belch, JJF, Forbes CD. The effect of a prostacyclin analogue (ZK36-374, Iloprost) on skin temperatures. Prostaglandins 1985; 19 (3): 301-303.

 

44.             Payton CD, Belch, JJF, Boulton-Jones JM. Successful treatment of thrombotic thrombocytopenia purpura by prostacyclin infusion. Lancet 1985; 1 (8434): 927-928.

 

45.             Greer IA, Winter JH, Gaffney D, McLoughlin K, Belch, JJF, Boyd G, Forbes CD. Platelet activation in allergic asthma. Thrombosis and Haemostasis 1985; 53 (3): 438.

 

46.             Morland JS, Porter JM, Kahaleh MB, Belch, JJF, Simms M. A multiclinic, placebo controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome. Annals of Rheumatic Diseases 1985; 44 (11): 754-760.

 

47.             McLaren M, Belch, JJF, Forbes CD, Prentice CRM. Development of a radioimmunoassay for the measurement of prostacyclin metabolites in unextracted plasma. Thrombosis Research 1985; 37 (1): 177-183.

 

48.             Belch, JJF, Madhok R, McArdle B, McLaughlin K, Forbes CD, Sturrock RD. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double-blind study of stanozolol. Quarterly Journal of Medicine 1986; 58 (225): 19-27.

 

49.             Manku MS, Morse N, Belch, JJF. Effects of gamma-linolenic acid supplementation on plasma essential fatty acids. Progress in Lipid Research 1986; 25: 469-473.

 

50.             Turi S, Belch, JJF, Beattie TJ, Forbes CD. Abnormalities of vascular prostaglandins in Henoch Schonlein vasculitis. Archives of Diseases in Childhood 1986; 61 (2): 173-177.

 

51.             Lowe GD, Ghafour IM, Belch, JJF, Forbes CD, Foulds WS, MacCuish AC. Increased blood viscosity in diabetic proliferative retinopathy. Diabetes Research 1986; 3( 2): 67-70.

 

52.             Turi S, Beattie TJ, Belch, JJF, Murphy AV. Disturbance of prostacyclin metabolism in children with haemolytic-uremic syndrome and in first degree relatives. Clinical Nephrology 1986; 25 (4): 193-198.

 

53.             Forwell MA, Pell GM, Froebel KS, Belch, JJF, MacSween RNM, Sandilands GP. Transfusion-induced Fc gamma-receptor-blocking antibodies: spectrum of cellular reactivity. Journal of Clinical Laboratory Immunology 1986; 20 (2): 63-67.

 

54.             Godfrey DG, Stimson WH, Watson J, Belch, JJF, Sturrock RD. Effects of dietary supplementation on auto-immunity in the MRL/1pr mouse: a preliminary investigation. Annals of Rheumatic Diseases 1986; 45 (12): 1019-1024.

 

55.             Greer IA, McLaren M, Belch, JJF, Lowe GDO, Forbes CD. Endothelial stimulation by DDAVP in von Willebrand’s disease and haemophilia. Haemostasis 1986; 16 (1): 15-19.

 

56.             Steven MM, Belch, JJF, Sturrock. Destructive arthritis in cutaneous polyarteritis nodosa. Arthritis and Rheumatism 1986; 29 (6): 812.

 

57.             Ansell D, Belch, JJF, Forbes CD. Depression and prostacyclin infusion. The Lancet 1986; 2 (8505): 509.

 

58.             Belch, JJF, Shaw B, O'Dowd A, Curran L, Forbes CD, Sturrock RD. Evening primrose oil (Efamol) as a treatment for cold-induced vasospasm (Raynaud's phenomenon). Progress in Lipid Research 1986; 25: 335-40.

 

59.             Belch, JJF, Madhok R, Forbes CD, Sturrock RD. Effect of increasing fibrinolysis in patients with rheumatoid arthritis. Orthopaedics/Rheumatology Digest 1986; 7: 11-12.

 

60.             Greer IA, McLaren M, Belch, JJF, Lowe GDO, Forbes CD. Desamino-8-d-arginine vasopressin and prostacyclin production in von Willebrand's disease. Progress in Lipid Research 1986; 25: 301-302.

 

61.             Godfrey DG, Stimson WH, Watson J, Belch, JJF, Sturrock RD. The modulation of autoimmunity in the MRL-mp-lpr/1pr mouse by dietary fatty acid supplementation. Progress in Lipid Research 1986; 25: 288-293.

 

62.             Belch, JJF, Drury J, Flannigan P, Anderson J, O'Dowd A, Sturrock RD, Forbes CD. Abnormal biochemical and cellular parameters in the blood of patients with Raynaud's Phenomenon. Scottish Medical Journal 1987; 32 (1): 12-14.

 

63.             Belch, JJF, O'Dowd A, Ansell D, Sturrock RD. Leukotriene B4 production in patients with rheumatoid arthritis. Clinical Rheumatology 1987; 6: 120-121.

 

64.             Belch, JJF, Saniabadi A, McLaren M, McLaughlin K, Forbes CD. Acute platelet changes after a saturated fat meal and their prevention by UK38,485, a potent thromboxane synthetase inhibitor. Lipids 1987; 22 (3): 159-162.

 

65.             Saniabadi AR, Belch, JJF, Lowe GDO, Barbenel JC, Forbes CD. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelets in whole blood. Haemostasis 1987; 17 (3): 147-153.

 

66.             Newman RJ, Belch, JJF, Kelly IG, Sturrock RD. Are combined orthopaedic and rheumatology clinics worthwhile? British Medical Journal 1987; 294 (6584): 1392-1393.

 

67.             Belch, JJF, Zoma A, McLaughlin K, Curran L, Cappel H, Forbes CD, Sturrock RD. Fibrinolysis in SLE: Effect of desamino-d-arginine vasopressin infusion. British Journal of Rheumatology 1987; 26 (4): 262-266.

 

68.             Belch, JJF, Zoma A, Richards I, Forbes CD, Sturrock RD. Vascular damage and factor VIII related antigen in the rheumatic disease. Rheumatology International 1987; 7 (3): 107-111.

 

69.             Belch, JJF, Saniabadi AR, Forbes CD. Whole blood white cell aggregation: a novel technique. Thrombosis Research 1987; 48 (6): 631-639.

 

70.             Belch JJF, Ansell D, Saniabadi A, Forbes CD, Sturrock RD. Transdermally applied iloprost (2K36-374) decreases whole blood platelet aggregation in normal volunteers. Progress in Clinical & Biological Research 1987; 242: 413-417.

 

71.             Belch, JJF, Ansell D, Madhok R, O'Dowd A, Sturrock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Annals of Rheumatic Diseases 1988; 47 (2): 96-104.

 

72.             Larkin JG, Belch, JJF, Flannigan P, Forbes CD, Frier BM. Microvascular disease and limited joint mobility in diabetes. A comparison of fibrinolysis and prostacyclin in diabetes and systemic sclerosis. Diabetic Medicine 1988; 5 (1): 53-56.

 

73.             Sunderland GT, Belch, JJF, Sturrock RD, Forbes CD, McKay AJ. A double blind randomised placebo controlled trial of Hexopal in primary Raynaud's disease. Clinical Rheumatology 1988; 7 (1): 46-49.

 

74.             Watson J, Godfrey D, Stimson WH, Belch, JJF, Sturrock RD. The therapeutic effects of dietary fatty acid supplementation in the auto-immune disease of the MRL-mp-lpr/1pr mouse. International Journal of Immunopharmacology 1988; 10 (4): 467-471.

 

75.             McKenzie J, Belch, JJF, Land D, Park R, McKillop J. Oesophageal ischaemia in motility disorders associated with chest pain. The Lancet 1988; 2 (8611): 592-595.

 

76.             Chopra M, Belch, JJF, Smith WE. A comparison of free radical scavenging activity of leukotrienes and prostaglandins. Free Radical Research Communications 1988; 5 (2): 95-99.

 

77.             Belch, JJF, Land D, Park RHR, McKillop JH, McKenzie JF. Decreased oesophageal blood flow in patients with Raynaud's phenomenon. British Journal of Rheumatology 1988; 27 (6): 426-430.

 

78.             Fisher TC, Belch, JJF, Barbenel JC, Fisher AC. In-vitro human whole blood granulocyte aggregation. Clinical Science 1989; 76 (2): 183-187.

 

79.             Belch, JJF, Chopra M, Hutchinson S, Lorimer R, Sturrock RD, Forbes CD, Smith E. Free radical pathology in chronic arterial disease. Free Radicals in Biology and Medicine 1989; 6(4): 375-378.

 

80.             Chopra M, Scott N, Smith WE, Belch, JJF. Captopril: A free radical scavenger. British Journal of Pharmacology 1989; 27 (3): 396-399.

 

81.             Belch, JJF, O'Dowd A, Ansell D, Sturrock RD. Leukotriene B4 production from white cells of patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 1989; 18 (4): 213-219.

 

82.             McCallion J, McLaren M, Belch, JJF, Erwin L. Effects of fenbufen and indomethacin on renal function and prostaglandin synthesis in elderly patients. Journal of Clinical and Experimental Gerontology 1989; 11 (3-4): 97-103.

 

83.             Saniabadi AR, Lowe GDO, Belch, JJF, Forbes CD. Platelet aggregation inhibitory effects of the new positive inotropic agents pimobendan and UDCG 212 in whole blood. Cardiovascular Research 1989; 23 (3): 184-190.

 

84.             Oldroyd K, Chopra M, Belch, JJF, Cobbe S. Lipid peroxidation during myocardial


ischaemia induced by pacing. British Heart Journal 1990; 63 (2): 88-92.

 

85.             McLaren M, Jennings PE, Forbes CD, Belch, JJF. Fibrinolytic response to venous occlusion in diabetics with and without micro-angiopathy compared to normal age and sex matched controls. Fibrinolysis 1990; 4 (2): 95-96.

 

86.             McLaren M, Bancroft A, Alexander W, Belch, JJF. Platelet aggregation in whole blood: Comparison between Clay Adam ultraflow-100 and Coulter haematology analyser T-540. Platelets 1990; 1: 95-96.

 

87.             Reglinski J, Smith WE, Belch, JJF. The action of Captopril at a cellular level. Journal of Chemical Research 1990; 1: 95-96.

 

88.             Saniabadi AR, Lowe G, Belch, JJF, Barbenel JC, Forbes CD. A platelet counting technique to study platelet aggregation in whole blood: application to pathologically low platelet counts. Platelets 1990; 1: 151-153.

 

89.             Saniabadi AR, Fisher TC, Belch, JJF, Forbes CD. A study of the effect of dipyridamole on erythrocyte deformability using an improved filtration technique. Clinical Haemorrheology 1990; 10: 263-274.

 

90.             McLaren M, Forbes CD, Belch, JJF. Measurement of thrombin generation using a microtitre plate method. Thrombotic and Haemorrhagic Disorders 1990; 1/2: 73-75.

 

91.             Chopra M, McMurray J, McLay J, Bridges A, Scott N, Smith WE, Belch, JJF. Oxidative damage in chronic heart failure. Protection by Captopril through free radical scavenging. Advances in Experimental Medicine and Biology 1990; 264: 251-256.

 

92.             McMurray J, McLay J, Chopra M, Bridges A, Belch, JJF. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology 1990; 65 (18): 1261-1262.

 

93.             Park RHR, McKillop JH, Belch, JJF, Faichney A, MacKenzie JF. Achlalasia-like syndrome in systemic sclerosis. British Journal of Surgery 1990; 77 (1): 46-49.

 

94.             McLaren M, Lau C, Forbes CD, Belch, JJF. Seasonal variation in fibrinolysis in patients with rheumatoid arthritis. Fibrinolysis 1990; 4 (2): 116-117.

 

95.             Saniabadi AR, Lowe GDO, Belch, JJF, Forbes CD. Further evidence that the residual von Willebrand factor antigen in porcine factor VIII coagulation factor induces human platelet aggregation. Haemostasis 1990; 20 (5): 289-295.

 

96.             Lang CC, Lau CS, Belch, JJF, Struthers AD. Effects of atrial natriuretic factor on platelet function in whole blood ex-vivo in man. European Journal of Clinical Pharmacology 1990; 39 (6): 589-591.

 

97.             The Ciprostene Study Group. The effect of Ciprostene in patients with peripheral vascular disease (PVD) characterised by ischaemic ulcers. Journal of Clinical Pharmacology 1991; 31 (1): 81-87.

 

98.             Saniabadi AR, Fisher TC, McLaren M, Belch, JJF, Forbes CD. Effect of Dipyridamole alone and in combination with aspirin on whole blood platelet aggregation, PGI2 generation and red cell deformability ex-vivo in man. Cardiovascular Research 1991; 25 (3): 177-83.

 

99.             Belch, JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. British Heart Journal 1991; 65 (5): 245-248.

 

100.         Bridges AB, McLaren M, Saniabadi AR, Fisher TC, Belch, JJF. Circadian rhythm of endothelial cell function, red blood cell deformability and dehydrothromboxane B2 in healthy volunteers. Blood Coagulation and Fibrinolysis 1991; 2 (3): 447-452.

 

101.         Bridges AB, Scott NA, Belch, JJF. Probucol, a superoxide free radical scavenger in vitro. Atherosclerosis 1991; 89 (2-3): 263-265.

 

102.         Lau CS, Gallacher C, Ross P, Belch, JJF. Rheumatoid arthritis - snake oil or fish oil? British Journal of Rheumatology 1991; 30 (1): 72-73.

 

103.         Lau CS, McLaren M, Saniabadi AR, Scott N, Belch, JJF. The pharmacological effects of cicaprost, an oral prostacyclin analogue in patients with Raynaud's syndrome secondary to systemic sclerosis. Clinical and Experimental Rheumatology 1991; 9 (3): 271-273.

 

104.         Scott N, Jennings PE, Brown J, Belch, JJF. Gliclazide: a general free radical scavenger. European Journal of Clinical Pharmacology 1991; 208 (2): 175-177.

 

105.         Belch, JJF, Lau C, McLaren M, Forbes CD. Iloprost and risk of thrombo-embolism. American Journal of Medicine 1991; 91 (6): 666-668.

 

106.         Jennings PE, MacEwan CJ, Fallon TJ, Scott N, Haining WM, Belch, JJF. Oxidative effects of laser photocoagulation. Free Radical Biology and Medicine 1991; 11 (3): 327-330.

 

107.         Jennings PE, McLaren M, Scott N, Saniabadi A, Belch, JJF. The relationship of oxidative stress to thrombotic tendency in type 1 diabetic patients with retinopathy. Diabetic Medicine 1991; 8 (9): 860-865.

 

108.         Jankowski J, Bridges AB, Scott N, Wormsley KG, Belch, JJF. Circulating free radical markers and peptic ulcer disease. European Journal of Gastro-enterology and Hepatology 1991; 3: 823-828.

 

109.         Lau CS, McLaren M, Belch, JJF. Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. British Journal of Rheumatology 1991; 30 (6): 433-436.

110.         Lau CS, Khan F, McLaren M, Bancroft A, Belch, JJF. The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatology International 1991; 11 (4-5): 163-168.

 

111.         Taylor JE, Bridges A, Henderson IS, Stewart WK, Belch, JJF. Whole blood granulocyte aggregation in dialysis-dependant patients. Blood Coagulation and Fibrinolysis 1991; 2 (6): 765-769.

 

112.         Taylor  JE, Henderson IS, Stewart WK, Belch, JJF. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. The Lancet 1991; 338 (8779): 1361-1362.

 

113.         Dawes J, McLaren M, Forbes C, Belch, JJF, Lane DA, Bray B, McEwen J, Houin G, Gianese F. Pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers. British Journal of Clinical Pharmacology 1991; 32 (3): 361-366.

 

114.         Lau CS, Scott N, Brown JE, Shaw W, Belch, JJF. Increased activity of oxygen free radicals during reperfusion in patients undergoing percutaneous peripheral artery balloon angioplasty. International Angiology 1991; 10 (4): 244-246.

 

115.         Lau C, O'Dowd A, Belch, JJF. White cell activation in the Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. Annals of Rheumatic Diseases 1992; 51(2): 249-252.

 

116.         Taylor JE, Belch, JJF, Henderson IS, Stewart WK. Platelet aggregation in erythropoietin treated haemodialysis patients. Platelets 1992; 3 (1): 47-52.

 

117.         Taylor JE, McLaren M, Stewart WK, Henderson IS, Belch JJF. Prothrombotic effect of erythropoietin in dialysis patients. Nephrology, Dialysis and Transplant 1992; 7 (3): 235-239.

 

118.         Khan F, Spence VA, Belch, JJF. Cutaneous vascular responses and thermoregulation in relation to age. Clinical Science 1992; 82 (5): 521-528.

 

119.         Taylor JE, Scott N, Bridges A, Henderson IS, Stewart WK, Belch, JJF. Lipid peroxidation and anti-oxidants in continuous ambulatory peritoneal dialysis patients. Peritoneal Dialysis International 1992; 12 (2): 252-256.

 

120.         Bridges AB, Scott N, Pringle TH, McNeill GP, Belch, JJF. Relationship between the extent of coronary artery disease and indicators of free radical activity. Clinical Cardiology 1992; 15 (3): 169-174.

 

121.         Wilson S, Jennings PA, Belch, JJF. Detection of microvascular impairment in type 1 diabetes by laser Doppler flowmetry. Clinical Physiology 1992; 12 (2): 195-208.

 

122.         Saniabadi AR, Fisher TC, Lau CS, Bridges A, Taylor J, Belch, JJF, Forbes CD. Dipyridamole increases human red cell deformability. European Journal of Clinical Pharmacology 1992; 42 (6): 651-654.

 

123.         Taylor JE, Mactier RA, Henderson IS, Belch, JJF, Stewart WK. Dialysis efficiency and blood rheology in continuous ambulatory peritoneal dialysis patients treated with erythropoietin. Peritoneal Dialysis International 1992; 12 (2): 221-226.

 

124.         Bridges AB, Fisher TC, Scott N, McLaren M, Belch, JJF. Circadian rhythm of white blood cell aggregation and free radical status in healthy volunteers. Free Radical Research Communications 1992; 16 (2): 89-97.

 

125.         Lau CS, Bridges A, Muir A, Scott N, Bancroft A, Belch, JJF. Further evidence of white cell activation in patients with Raynaud's phenomenon. British Journal of Rheumatology 1992; 31 (6): 375-380.

 

126.         Bridges AB, Pringle T, McNeill G, Belch, JJF. Beta-adrenoceptor antagonists enhance white blood cell aggregation in patients with ischaemic heart disease. British Journal of Clinical Pharmacology 1992; 34 (3): 272-274.

 

127.         Taylor JE, McLaren M, Mactier RA, Henderson IS, Stewart WK, Belch, JJF. The effect of dialyser geometry on platelet and granulocyte activation during haemodialysis with cuprophane membranes. Kidney International 1992; 42 (2): 442-447.

 

128.         Jennings PE, Scott NA, Saniabadi AR, Belch JJF. Effects of Gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism 1992; 41 (5): 36-39.

 

129.         Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch, JJF. Circadian variation in white blood cell aggregation and free radical indices in men with stable ischaemic heart disease. European Heart Journal 1992; 13 (12): 1632-1636.

 

130.         Bridges AB, McLaren M, Pringle T, Belch JJF. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen and prostacyclin stimulating factor in men with ischaemic heart disease. British Heart Journal 1993; 69 (2): 121-124.

 

131.         Belch, JJF, Diehm C, Henry M, Rieger H, Rudofsky G, Frings M, Hornig F, Sohngen W. Evaluating treatment of critical limb ischaemia: for the European PARTNER concept study groups. Critical Ischaemia 1993; 2 (4): 4-12.

 

132.         Bridges AB, Scott NA, Parry GJ, Belch, JJF. The effects of age, sex and smoking on indices of free radical activity in healthy humans. European Journal of Medicine 1993; 2 (4): 205-208.

 

133.         Belch, JJF, McLaren M, Lau CS, McKay IR, Saniabadi AR, Bancroft A, McEwen J, Thompson JM. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers. British Journal of Clinical Pharmacology 1993; 35 (6): 643-647.

 

134.         Bridges AB, Hill A, Belch, JJF. Cigarette smoking increases white blood cell aggregation in whole blood. Journal of the Royal Society of Medicine 1993; 86 (3): 139-140.

 

135.         Bridges AB, Scott N, McNeill G, Belch JJF. Free radical markers in patients with angina pectoris and normal coronary angiograms. Cardiology 1993; 82 (1): 7-11.

 

136.         Bridges AB, McLaren M, Pringle T, McNeill G, Belch JJF. Endothelial dysfunction in acute myocardial infarction following reperfusion. American Heart Journal 1993; 126 (2): 452-453.

 

137.         Lau CS, McLaren M, MacKay IR, Belch JJF. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. Annals of Rheumatic Diseases 1993; 52 (6): 443-448.

 

138.         Leese G, Belch JJF, Ricklauss P, Nimmo M. Post-traumatic axillary artery thrombosis dissolution with low-dose intra-arterial streptokinase. Injury: The British Journal of Accident Surgery 1993; 24 (3): 212-213.

 

139.         Taylor JE, Belch JJF, McLaren M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in haemodialysis patients. Kidney International 1993; 44 (1): 182-190.

 

140.         Lau CS, McLaren M, Hanslip J, Kerr M, Belch JJF. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Annals of Rheumatic Diseases 1993; 52 (9): 643-649.

 

141.         Lau CS, McLaren M, Saniabadi A, Belch JJF. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with and without systemic sclerosis. Scandinavian Journal of Rheumatology 1993; 22 (3): 97-101.

 

142.         Taylor JE, Scott N, Hill A, Bridges A, Henderson IS, Stewart WK, Belch JJF. Oxygen free radicals and platelet and granulocyte aggregability in renal transplant patients. Transplantation 1993; 55 (3): 500-504.

 

143.         Lau CS, Morley KD, Belch JJF. Effects of Maxepa fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis. British Journal of Rheumatology 1993; 32 (11): 982-989.

 

144.         Bridges AB, McLaren M, Gray J, McNeill G, Belch JJF. Endothelial cell function in Marfan Syndrome. Endothelium, Journal of Endothelial Cell Research 1993; 1: 203-206.

 

145.         Lowe GDO, Belch JJF, Bell PRF, Coleridge Smith PD, Dormandy JA, Fowkes FGR, Gaines PA, Housley F, Jayson MIV, Nicolaides A, Roberts VC, Tooke JE. Medical angiologists: Britain needs them. British Medical Journal 1993; 307 (6896): 127-128.

 

146.         Belch JJF, McLaren M, Cavangh EA, MacKay IR, Davey PG. No effect of endotoxin on platelet aggregation. Platelets 1993; 4: 285-286.

 

147.         Belch JJF, Veale DJ, Coleridge T. Large vessel occlusive disease in systemic sclerosis. Annals of Rheumatic Disease 1993; 52 (11): 837-838.

 

148.         Lau CS, Belch JJF, Madhok R, Capell H, Herrick A, Jayson M, Thompson JM. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Clinical & Experimental Rheumatology 1993; 11 (1): 35-40.

 

149.         Lau CS, Belch JJF. The in vitro free radical scavenging effects of tenidap, a dual cyclo-oxygenase and 5-lipoxygenase inhibitor. Mediators of Inflammation 1993; 1(2): 141-143.

 

150.         Leese GP, Belch JJF. Erythromelalgia associated with malignant platelet transformation. Proceedings of the Royal College of Physicians Edinburgh 1994; 24: 65-67.

 

151.         Veale DJ, Torley H, Richards IM, O’Dowd A, Fitzsimons C, Belch JJF, Sturrock RD. A double-blind placebo controlled trial of Efamol marine on skin and joint symptoms of psoriatic arthritis. British Journal of Rheumatology 1994; 33 (10): 954-958.

 

152.         Tait IS, Holdsworth RJ, Belch JJF, McCollum PT. Management of intra-arterial injection injury with iloprost. The Lancet 1994; 343 (8894): 419.

 

153.         Abbot NC, Spence VA, Lowe JG, Potts RC, Hasson AHA, Belch JJF, Beck JS. The association between immune activation and presumed cutaneous anergy in post-viral fatigue syndrome. British Medical Journal 1994; 308 (6939): 1299.

 

154.         Taylor JE, Belch JJF, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clinical Nephrology 1994; 41 (5): 297-302.

 

155.         Taylor JE, Belch JJF, Henderson IS, Stewart WK. Erythropoietin does not increase whole-blood platelet aggregation in vitro. Nephrology Dialysis & Transplantation 1994; 9 (5): 556-558.

 

156.         Veale DJ, Muir AH, Morley KD, Belch JJF. Treatment of vasculitic leg ulcers in connective tissue disease with iloprost. Clinical Rheumatology 1995; 14 (2): 1345-1348.

 

157.         Lau CS, Khan F, Brown R, Wilson SB, Belch, JJF. Digital blood flow response to whole body warming, cooling and rewarming in patients with Raynaud's phenomenon. Angiology 1995; 46 (1): 1-10.

 

158.         Belch JJF, Capell HA, Cooke ED, Kirby JDT, Lau CS, Madhok R, Murphy E, Steinberg M. Oral iloprost as a treatment for Raynaud’s syndrome: A double-blind multi-centre placebo controlled study. Annals of Rheumatic Diseases 1995; 54 (3): 197-200.

 

159.         Lau CS, Saniabadi AR, Belch JJF. Reduced red cell deformability in patients with rheumatoid vasculitis: improvement after in-vitro treatment with dipyridamole. Arthritis & Rheumatism 1995; 38 (2): 248-253.

 

160.         Bridges AB, McNeill GP, Pringle TH, Belch JJF. A late increase in free radical activity post myocardial infarction. European Heart Journal 1995; 16 (7): 899-902.

 

161.         Bridges AB, McLaren M, Belch JJF. A comparative study of Captopril and Enalapril on endothelial cell function in congestive heart failure patients. Angiology 1995; 46 (9): 811-817.

 

162.         Taylor JE, Belch JJF, McLaren M, Stewart WK. Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin. Blood Coagulation & Fibrinolysis 1995; 6 (2): 100-104.

 

163.         Kirk G, Maple C, McLaren M, Burslem F, Belch JJF. A circadian rhythm exists in healthy controls for soluble P-Selectin and platelet count. Platelets 1995; 6 (6): 414-415.

 

164.         Hanna GB, Newton DJ, Harrison DK, Belch JJF, McCollum P. The use of lightguide spectrophotometry in quantifying skin oxygenation in a variable model of venous hypertension. British Journal of Surgery 1995; 82 (10): 1352-1356.

 

165.         Veale DJ, Collidge TA, Belch JJF. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Annals of Rheumatic Disease 1995; 54 (10): 853-855.

 

166.         Lau CS, McLaren M, Belch JJF. Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis. Clinical & Experimental Rheumatology 1995; 13 (1): 87-90.

 

167.         Belch JJF, Mackay IR, Hill A, Jennings P, McCollum P. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. International Angiology 1996; 14 (4): 385-388.

 

168.         Belch JJF, Diehm C, Sohngen M, Sohngen W. Critical limb ischaemia: A case against Consensus II. International Angiology 1996; 14 (4): 353-356.

 

169.         Taylor JE, Belch, JJF, Henderson IS, Stewart WK. Peripheral microcirculatory blood flow in haemodialysis patients treated with erythropoietin. International Angiology 1996; 15 (1): 33-38.

 

170.         Verstraete M, Belch JJF, Dormandy JA, Verhaege R. Thrombolysis in the management of limb arterial occlusion. Towards a consensus. Interim Report. Journal of Internal Medicine 1996; 240: 82-96.

 

171.         Martin W, Carter R, Tweddel A, Belch JJF, El-Fiky M, McQuiston AM, McLaren M, Wheatley DJ. Respiratory dysfunction and white cell activation following cardiopulmonary bypass: comparison of membrane and bubble oxygenators. European Journal of Cardiothoracic Surgery 1996; 10 (9): 774-783.

 

172.         Belch JJF, Greene SA, Litttleford R, Jennings PE, Khan F. Impaired skin blood flow response to heat in children with insulin dependent diabetes. International Journal of Angiology 1996; 5: 189-191.

 

173.         Mulherin DM, Veale DJ, Belch JJF, Bresnihan B, Fitzgerald O. Synovial membrane expression and soluble adhesion molecule levels in previously untreated inflammatory arthritis. Quarterly Journal of Medicine 1996; 89 (3): 195-203.

 

174.         Stonebridge PA, Hoskins PR, Allan PL, Belch JJF. Spiral laminar flow in vivo. Clinical Science 1996; 91 (1): 17-21.

 

175.         Belch JJF, Shaw JW, Kirk G, McLaren M, Robb R, Maple C, Morse P. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 1997; 95 (8): 2027-2031.

 

176.         Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RC, Belch JJF. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis & Rheumatism 1997; 40 (2): 352-357.

 

177.         Belch JJF, Bell PRF, Coleridge-Smith P, Creissen D, Dormandy JA, Kester RC, McCollum RD, Mizushima Y, Ruckley CV, Scurr JH, Wolfe JHN. A randomized double-blind placebo controlled study evaluating the efficacy and safety of AS-013, a PGE1 prodrug in patients with intermittent claudication. Circulation 1997; 95 (9): 2298-2302.

 

178.         Kirk G, McLaren M, Belch JJF. Soluble P-selectin assay: importance of correct anticoagulant choice. Platelets 1997; 8: 159-162.

 

179.         Abel EW, Inglis S, Liu Y, Belch JJF, Koop A. A high speed gated baseline restorer and its implementation in a blood cell volume analyser. Medical Engineering & Physics 1997; 19(3): 267-272.

 

180.         Littleford RC, Khan F, Hindley MO, Ho M, Belch JJF. Microvascular abnormalities in patients with vibration white finger. Quarterly Journal of Medicine 1997; 90 (8): 525-529.

 

181.         Butler AR, Field RA, Greing IR, Flitney FW, Bisland SK, Khan FK, Belch JJF.  An examination of some derivatives of S-nitroso-I-thiosugars as vasodilators.  Nitric Oxide:  Biology & Chemistry 1997; 1(3): 211-217.

 

182.         Elhadd TA, Bancroft A, McLaren M, Newton RW, Belch JJF.  Increased granulocyte aggregation in vitro in diabetes mellitus.  Quarterly Journal of Medicine 1997; 90 (7): 461-464.

 

183.         Khan F, Davidson NC, Littleford RC, Litchfield SJ, Struthers AD, Belch JJF.  Cutaneous vascular responses to acetylcholine are mediated by prostanoid-dependent  mechanism in man. Vascular Medicine 1997; 2 (2): 82-86.

 

184.         Khan F, Grieg IR, Newton DJ, Butler A, Belch JJF.  Skin blood flow after transdermal S-nitrosothio-acetylglucose.  The Lancet 1997; 350(9075): 410-411.

 

185.         Elhadd TA, Jennings PE, Belch JJF. Oxidative stress and diabetic vascular complications in young IDDM patients. Diabetes Care 1997; 20 (8): 1338-1339.

 

186.         Lau CS, Belch JJF. Lack of correlation between red cell membrane incorporation of essential fatty acids and disease activity and severity variables of rheumatoid arthritis. APLAR Journal of Rheumatology 1997; 1 (2): 88-91.

 

187.         Maple C, Kirk G, McLaren M, Veale D, Belch JJF.  A circadian variation exists for soluble levels of intracellular adhesion molecule-1 and E-selectin in healthy volunteers. Clinical Science 1998; 94 (5): 537-540.

 

188.         Veale DJ, Maple C, Kirk G, McLaren M, Belch JJF. Soluble cell adhesion molecules  - P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scandinavian Journal of Rheumatology 1998; 27 (4): 296-299.

 

189.         Working Party on Thrombolysis in the management of Limb Ischaemia. Thrombolysis in the management of lower limb peripheral arterial occlusion - A consensus document. American Journal of Cardiology 1998; 81: 207-218.

 

190.         Belch JJF, McLaren M, Hanslip J, Hill A, Davidson D. The white blood cell and plasma fibrinogen in thrombotic stroke. International Angiology 1998; 17 (2): 120-124.

 

191.         Maple C, McLaren M, Ho M, Belch JJF. Dietary supplementation with Omega 3 and Omega 6 fatty acids reduces increased white blood white blood cell aggregation in healthy volunteers. Prostaglandins, Leukotrienes & Essential Fatty Acids 1998; 58 (5): 365-368.

 

192.         Elhadd TA, Khan F, Kirk G, McLaren M, Newton RW, Greene S, Belch JJF. Influence of puberty on markers of endothelial dysfunction and oxidative stress in children and young people with Type-1 (insulin-dependent) diabetes. Diabetes Care 1998; 21 (11): 1990-1996.

 

193.         Black CM, Halkier-Sorensen L, Belch JJF, Ullman S, Madhok R, Smit AJ, Borga J-D, Watson HR. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: A multicenter placebo-controlled, dose-comparison study. British Journal of Rheumatology 1998; 37 (9): 952-960.

 

194.         Veale DJ, Kirk G, McLaren M, Belch JJF. Clinical implications of soluble intercellular adhesion molecule-1 levels in a systemic disease - scleroderma. British Journal of Rheumatology 1998; 37 (11): 1227-1229.

 

195.         Kirk G, McLaren M, Muir A, Stonebridge PA, Belch JJF. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid lowering treatment. Vascular Medicine 1999; 4 (1): 23-26.

 

196.         Elhadd TA, Kirk G, McLaren M, Newton RW, Greene S, Belch JJF. Endothelial integrity, soluble adhesion molecules and platelet markers in Type 1 diabetes mellitus. Diabetic Medicine 1999; 16 (1): 86-87.

 

197.         McLaren M, Elhadd TA, Greene SA, Belch JJF. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Thrombosis and Haemostasis 1999; 5: 21-24.

 

198.         Belch JJF, Ho M. Causes of mortality in systemic sclerosis. Rheumatology 1999; 38 (3): 283-290

 

199.         Elhadd TA, Newton RW, Jennings PE, Belch JJF. Antioxidant effects of gliclizide and soluble adhesion molecules in Type 2 diabetes mellitus. Diabetes Care 1999; 22 (3): 528-530.

 

200.         Belch JJF, Sohngen M, Robb R, Voleske P, Sohngen W. Neutrophil count and amputation in critical limb ischaemia. International Angiology 1999; 18 (2): 139-144.

 

201.         Kirk G, Hickman P, McLaren M, Stonebridge PA, Belch JJF. Interleukin-8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). European Journal of Vascular and Endovascular Surgery 1999; 18 (5): 434-438.

 

202.         Kennedy G, Khan F, McLaren M, Belch JJF. Endothelial activation and vascular responses in patients with Raynaud's phenomenon secondary to Hand/Arm Vibration Syndrome. European Journal of Clinical Investigation 1999; 29 (7): 577-581.

 

203.         Elhadd TA, Robb R, Jung RT, Stonebridge PA, Belch JJF. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Practical Diabetes International 1999; 16(6): 163-166.

 

204.         Littleford RC, Khan F, Belch JJF. Skin perfusion in patients with erythromelalgia. European Journal of Clinical Investigation 1999; 29 (7): 588-593.

 

205.         Khan F, Belch JJF. Skin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: the effects of oral L-arginine supplementation. Journal of Rheumatology 1999; 26 (11): 2389-2394.

 

206.         Littleford RC, Khan F, Belch JJF. Impaired skin vasomotor reflexes in patients with erythromelalgia. Clinical Science 1999; 96 (5): 507-512.

 

207.         Ho M, Maple C, Bancroft A, McLaren M, Belch JJF. The beneficial effects of Omega-3 and Omega-6 essential fatty acid supplementation on red blood cell rheology. Prostaglandins, Leukotrienes & Essential Fatty Acids 1999; 61(1): 13-17.

 

208.         Elhadd TA, Kennedy G, Hill A, McLaren M, Newton RW, Greene SA, Belch JJF. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with Type-1 diabetes with no clinical vascular disease. Diabetes Metabolism, Research & Reviews 1999; 15 (6): 405-411.

 

209.         Taylor JE, Porter C, Heptinstall M, McLaren M, Belch JJF. Increased platelet activation in renal transplant patients. Platelets 1999; 10: 223-227.

 

210.         Kennedy G, McLaren M, Belch JJF, Seed M. Elevated levels of sE-selectin in post-menopausal females are decreased by Hormone Replacement Therapy to levels observed in pre-menopausal females. Thrombosis & Haemostasis 1999; 82 (5): 1433-1436.

211.         Khan F, Litchfield SJ, Stonebridge PA, Belch JJF. Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease. Vascular Medicine 1999; 4 (4): 233-238.

212.         Watson H, Robb R, Belcher G, Belch JJF. Seasonal Variation of Raynaud’s Phenomenon secondary to Systemic Sclerosis. British Journal of Rheumatology 1999; 26 (8): 1734-1737.

213.         Elhadd T, Kennedy G, McLaren M, Belch JJF, Clayton R. Monocyte adhesion and adhesion molecules in growth hormone deficient adults. Journal of Clinical Endocrinology & Metabolism 1999; 84 (9): 3405-3406.

 

214.         Khan F, Elhadd TA, Greene SA, Belch JJF. Impaired skin microvascular function in children, adolescents and young adults with Type-1 (insulin-dependent) diabetes mellitus. Diabetes Care 2000; 23 (2): 215-219.

 

215.         Ho M, Veale JD, Eastmond C, Nuki G, Belch JJF. Macrovascular disease and systemic sclerosis. Annals of Rheumatic Diseases 2000; 59 (1): 39-43.

 

216.         Elhadd TA, Kennedy G, McLaren M, Stonebridge PA, Shaw WJ, Belch JJF. Elevated levels of soluble E-selectin in diabetic patients with severe symptomatic peripheral arterial occlusive disease requiring angioplasty. International Angiology 2000; 19 (2): 171-175.

 

217.         Spence VA, Khan F, Belch JJF. Enhanced sensitivity of peripheral cholinergic vascular responses in patients with chronic fatigue syndrome. American Journal of Medicine 2000; 108: 736-739.

 

218.         Butler R, Morris AD, Belch JJF, Hill A, Struthers AD. Allopurinol normalises endothelial dysfunction in type 2 diabetes with mild hypertension. Hypertension 2000; 35: 746-751.

 

219.         Bancroft A, Abel EW, McLaren M, Belch JJF. Mean platelet volume is a useful parameter: a reproductive routine method using a modified Coulter thrombocytometer. Platelets 2000; 11 (7): 379-387.

 

220.         McEwan SR, Dewhurst NG, Daly F, Forbes CD, Belch JJF. Results of a survey of cardiovascular risk factor prevalence amongst health care workers. The Executive Committee of SHARP: Scottish Medical Journal 2000; 45 (3): 84-85.

 

221.         McEwan SR, Daly F, Forbes CD, Hawthorne VM, Belch JJF. Vascular risk factor profiles in the first phase of the Scottish Heart and Arterial Risk Prevention (SHARP) Survey. International Angiology 2000; 19 (3): 197-205.

 

222.         McLaren M, Kirk G, Bolton-Smith C, Belch JJF. Seasonal variation in plasma levels of endothelin-1 and nitric oxide. International Angiology 2000; 19: 351-353.

 

223.         Newton DJ, Burke D, Khan F, McLeod GA, Belch JJF, McKenzie M, Bannister J. Skin blood flow changes in response to intradermal injection of Bupivacaine and Levobupivacaine assessed by laser Doppler imaging. Regional Anaesthesia and Pain Medicine 2000; 25 (6): 626-631.

 

224.         Newton D, Leese G, Harrison D, Belch JJF. Microvascular abnormalities in diabetic foot ulcers. The Diabetic Foot 2001; 4: 141-146.

 

225.         Al-Allaf AW, Khan F, Moreland J, Belch JJF, Pullar T. Investigation of cutaneous microvascular activity and flare response in patients with fibromyalgia syndrome. Rheumatology 2001; 40: 1097-1101.

 

226.         Della Rossa A, Valentini G, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S, Cerinic MM, Belch JJF, Black CM, Becvar R, Bruhlman P, Cozzi F, Czirják L, Drosos AA, Dziankowska B, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Scorza R, Tirri E, van den Hoogen FHJ, Vlachoyiannoupoulos PG. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Annals of the Rheumatic Diseases 2001; 60: (6) 585-591.

 

227.         McEwan SR, Daly F, Forbes CD, Belch JJF. The Scottish Heart & Arterial Risk Prevention (SHARP) survey of cardiovascular risk: regional differences. Scottish Medical Journal 2001; 46: 108-110.

 

228.         Newton DJ, Khan F, Belch JJF. Assessment of microvascular endothelial function in human skin. Clinical Science 2001; 101: 567-572.

 

229.         Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S, Matucci Cerinic M, Belch JJF, Black CM, Bruhlmann P, Czirják L, De Luca A, Drosos AA, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Rosada M, Scorza R, Stork J, Sysa A, van den Hoogen FHJ, Vlachoyiannopoulos PJ. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Annals of the Rheumatic Diseases 2001; 60 (6): 592-598.

 

230.         Duprez D, Allegra C, Bauersachs R, Belch JJF, Boccalon H, Hoffmann U, Mahler F. Vascular centers in Europe. International Angiology 2002; 96-98.

 

231.         Young V, Ho M, Vosper H, Belch JJF, Palmer CNA. Elevated expression of the genes encoding TNF-a and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology 2002; 41: 869-875.

 

232.         Elherik K, Khan F, McLaren M, Kennedy G, Belch JJF. Circadian variation in vascular tone and endothelial cell function in normal males. Clinical Science 2002; 102: 547-552.

 

233.         McGrath C, Robb R, Lucas AJ, Stewart AHR, Underwood CL, Horridge JK, Lamont PM, Smith FCT, Baird RN and Belch JJF. A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. European Journal of Vascular and Endovascular Surgery 2002; 23: 381-387.

 

234.         Elhadd T, Abdu TA, Oxtoby J, Kennedy G, McLaren M, R Neary R, Belch JJF, Clayton R. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. Journal of Clinical Endocrinology & Metabolism 2002; 86: 4223-4232.

 

235.         Newton DJ, Khan F, Belch JJF, Mitchell MR, Leese GP. Blood Flow Changes in Diabetic Foot Ulcers Treated with Dermal Replacement Therapy. Journal of Foot and Ankle Surgery 2002: 41: 233-237

 

236.         McLaren M, Alkaabi J, Connacher M, Belch JJF, Valenete E. Activated factor XII in rheumatoid arthritis. Rheumatology International 2002; 22: 182-184

 

237.         McLaren M, Newton DJ, Khan F, Belch JJF. Vascular endothelial growth factor in patients with critical limb ischaemia before and after amputation. International Angiology 2002; 21: 165-168

 

238.         Muir AH, Robb R, McLaren M, Daly F, Belch JJF. The use of Ginkgo Biloba in Raynaud’s Disease:  A double-blind placebo-controlled trial.  Vascular Medicine 2002; 7: 265-267.

 

239.         Belch JJF, McLaren M, Khan F, Hickman P, Muir A, Stonebridge P. The inflammatory process in intermittent claudication. European Heart Journal 2002; 4: 31-34.

 

240.         Sun J, Abel EW, Bancroft A, McLaren M, Belch JJF. A study of whole blood platelet and white cell aggregation using a laser flow aggregometer. Platelets 2002; 14: 103-108.

 

241.         Newton DJ, Amyes AKB, Khan F, McLeod GA, Bannister J, Belch JJF. Vasoactive properties of lignocaine administered by iontophoresis in human skin. Clinical Science 2003; 104: 87-92

 

242.         Newton DJ, Sur EL, Khan F, McLeod GA, Belch JJF. Mechanisms contributing to the vasoactive effects of prilocaine in human skin.  Anasthesia 2003; 58: 6-10.

 

243.         Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJF. Rheumatoid arthritis and macrovascular disease. Rheumatology 2003: 42 (2); 292-297

 

244.         Palmer CAN, Young V, Ho M, Doney A, Belch JJF. Association of common variation in glutathione S-transferase genes with premature development of cardiovascular disease in patients with systemic sclerosis. Arthritis & Rheumatism 2003; 48 No 3: 854-855.

 

245.         Gervaz P, Holdsmith RJ, Naidu S, Houston JG, Belch JJF, McCollum PT. Emergency spleno renal bypass: A case report. Journal of the Royal College of Surgeons, Edinburgh (in press).

 

246.         Belch JJF, Topol EJ, Agnelli G, Bertrand M, Califf, RM, Clement DL, Creager MA, Easton JD, Gavin III JR, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA. Critical issues in peripheral arterial disease detection and management: A call to action. Archives of Internal Medicine (in press).

 

247.         Houston JG, Gandy SC, Allen L, Dick JBC, Belch JJF, Stonebridge PA. Spiral laminar flow in the abdominal aorta: A Predictor of Renal Impairment Deterioration in Patients with Renal Artery Stenosis? (in press).

 

 

 

COMMISSIONED EDITORIALS AND COMMENTS

 

 

1.                  Belch, JJF, Sturrock RD. Raynaud's syndrome: Current trends. (Comment). British Journal of Rheumatology 1983; 22 (1): 50-55.

 

2.                  Belch, JJF. Fish oil and rheumatoid arthritis. (Leader). Annals of Rheumatic Diseases 1990; 49 (2): 71-72.

 

3.                  Belch, JJF. Non-coronary thrombolysis. (Editorial). The Lancet 1990; 335: 691-693.

 

4.                  Belch, JJF. An update on the Phenomenon, syndrome and disease of Maurice Raynaud. (Editorial). British Journal of Rheumatology 1990; 29 (3): 162-165.

 

5.                  Belch, JJF. Fishing for an arthritis remedy. (Comment). Hospital Doctor 1991; C11 (17): 40.

 

6.                  Belch, JJF. Raynaud's Phenomenon: it's relevance to scleroderma. (Comment). Annals of Rheumatic Diseases 1991; 50 (4): 839-845.

 

7.                  Belch, JJF. Vasculitis (Editorial). Vascular Medicine Review 1992; 3: 1-2.

 

8.                  Belch, JJF. Is there a role for natural remedies in rheumatoid arthritis? (Comment). Scottish Medical Journal 1992; 37 (4): 100-102.

 

9.                  Belch, JJF. Free radicals and their scavenging in stroke. (Comment). Scottish Medical Journal 1992; 37 (3): 67-68.

 

10.             Belch JJF. The clinical assessment of scleroderma spectrum disorders. (Editorial) British Journal of Rheumatology 1993; 32 (5): 353-356.

 

11.             Belch JJF. The role of the white blood cell in thrombosis. (Editorial). Current Medical Literature: Thrombosis 1993; 3(3): 63-67.

 

12.             Belch JJF, McCollum P, Shaw JW. A multidisciplinary approach to vascular disease. (Comment). Critical Limb Ischaemia 1994; 3(3): 81-86.

 

13.             Belch JJF, Muir A. Free radicals and peripheral arterial disease. (Editorial). The International Monitor in Peripheral Vascular Disease 1997; 4: 1-3.

 

14.             UK Scleroderma Group. How can treatment of systemic sclerosis be improved? British Medical Journal 1998; 317: 294.

 

15.             Ho M, Belch JJF. Raynaud’s Phenomenon: State of the Art 1998. Scandinavian Journal of Rheumatology 1998; 27 (5): 319-322.

 

16.             Belch JJF, Khan F. Primary Raynaud's is a disease or a disorder: It is not merely a trait. (Editorial). Journal of Rheumatology 1998; 25 (12): 2295-2297.

 

 

COMMISSIONED REVIEWS

 

 

1.                  Belch, JJF, Sturrock RD. The management of polymyalgia rheumatica and temporal arteritis. Prescribers' Journal 1987; 27 (2): 27-29.

 

2.                  Belch, JJF. Raynaud's phenomenon. In: Reports on Rheumatic Diseases (Series 2), Hawkins C, Currey H, Dieppe P (eds). ARC Press: London 1987: 6.

 

3.                  Belch, JJF. Eicosanoids and rheumatology: Inflammatory and vascular aspects. In: Prostaglandins, Leukotrienes and Essential Fatty Acids Reviews 1989; 36 (4): 219-234.

 

4.                  Belch, JJF. Raynaud's phenomenon. Current Opinion in Rheumatology 1989; 1 (4): 490-498.

 

5.                  Belch, JJF. The management of Raynaud's phenomenon. Hospital Update 1990; 16 (5): 391-400.

 

6.                  Belch, JJF. The role of the white blood cell in arterial disease. Blood Coagulation and Fibrinolysis 1990; 1 (2): 183-191.

 

7.                  Belch, JJF. Raynaud's phenomenon. Current Opinion in Rheumatology 1990; 2 (6): 937-941.

                                         

8.                  Belch, JJF. The white blood cell as a risk factor for thrombotic vascular disease. Vascular Medicine Review 1990; 1 (2): 203-214.

 

9.                  Belch, JJF. Management of Raynaud's phenomenon. General Practitioners Update 1990; 41 (4): 253-260.

 

10.             Lau CS, Belch, JJF. Raynaud's phenomenon - a vasospastic disorder. Current Practice in Surgery 1991; 3: 170-175.

 

11.             Belch, JJF. Raynaud's phenomenon. Current Opinion in Rheumatology 1991; 3 (6): 960-966.

 

12.             Belch, JJF. Platelets and free radicals. Platelets 1992; 3:175-180.

 

13.             Belch, JJF, Mackay IR. Erythromelalgia - symptom or syndrome? Vascular Medicine Review 1992; 3: 31-39.

 

14.             Belch, JJF. Erythromelalgia - a personal view. Journal of Dermatological Treatments 1992; 3: 31-39.

 

15.             Belch JJF, Mackay IR, Hillis S. Thrombolysis in peripheral vascular disease. Vascular Medicine Review 1993; 4 (2): 111-116.

 

16.             Veale DJ, Belch JJF. The management of Raynaud's phenomenon. Rheumatology Review 1993; 2: 133-145.

 

17.             Veale DJ, Belch JJF. A physician's approach to vasospasm. Scottish Medical Journal 1993; 38 (5): 133-135.

 

18.             Belch JJF. Treatment options in Raynaud’s Phenomenon. In: International Symposium on Critical Limb Ischaemia. Eikelboom BC (Ed). Adis International Limited 1993; 21-30.

 

19.             Belch JJF. Evaluating and treating Raynaud's phenomenon. Prescriber 1994; 5(2): 47-58.

 

20.             Belch, JJF. The white blood cell and vascular disease. Journal of the Royal Society of Medicine 1994; 87: 364-365.

 

21.             Belch JJF. The relationship between white blood cells and arterial disease. Current Opinion in Lipidology 1994; 5 (6): 440-446.

 

22.             Hickman P, McCollum PT, Belch JJF. Neutrophils may contribute to the morbidity and mortality of claudicants. British Journal of Surgery 1994; 81 (6): 790-798.

 

23.             Hickman P, Belch JJF. The white blood cell and peripheral arterial disease. International Angiology 1994; 13 (1): 40-47.

 

24.             Belch JJF. Practical considerations on the use of iloprost in critical limb ischaemia and Raynaud’s phenomenon. Critical Limb Ischaemia 1995; 59-70.

 

25.             Belch JJF, Ho M. Pharmacotherapy of Raynaud’s phenomenon. Drugs 1996; 52 (5): 682-695.

 

26.             Belch JJF. Mystery Series: Raynaud’s phenomenon. Cardiovascular Research 1997; 33 (1): 25-30.

 

27.             Belch JJF, Muir A. n-6 and n-3 Essential fatty acids in rheumatoid arthritis and other rheumatic conditions. Proceedings of the Nutrition Society 1998; 57 (4): 563-569.

 

28.             Belch JJF. Myocardial infarction, ischaemic stroke and peripheral arterial disease: Common pathology, common perspective. Views in Vascular Disease 1999: 1-7.

 

29.             Belch JJF, Hill A. Evening Primrose oil and borage oil in rheumatological conditions. Bendich A, Connor W (eds). American Journal of Clinical Nutrition 2000; 71 (1): 352-356.

 

30.             Adam DJ, Stonebridge PA, Belch JJF, Murie JA. Antiplatelet and anticoagulant therapy to prevent bypass graft thrombosis in patients with lower extremity arterial occlusion. International Angiology 2001; 20 (1): 90-98.

 

31.             Belch JJF. Metabolic, endocrine and haemodynamic risk factors in the patient with peripheral arterial disease. Diabetes, Obesity and Metabolism 2002; 4 (Suppl 2), 7-13

 

32.             Belch JJF. Connective tissue disease. Hospital Update (in press).

 

33.             Belch JJF, Pedersen T. Peripheral arterial disease: identification and intervention with statins to reduce cardiovascular events.

 

34.             Belch JJF, Agnelli G, Badinon L, Bertrand M, Califf RM, Clement DL, Creager M, Easton JD, Gavin JR, Greenland P, Hankey G, Hanrath P, Hirsch A, Meyer J, Pearson TA, Smith SC, Sullivan F, Weber M. Critical issues associated with peripheral arterial disease. Call for action (in press).

 

35.             Carion R, Peeters PAM, Forbes CD, Belch JJF, Lowe GDO, Shaw BG, Rumley A, Necciari J, Dickinson JP. Clopidogrel compatibility with cardiac co-medication: studies of interaction with a β-blocker, a calcium uptake antagonist and a cardiac glycoside. Pharmacology & Therapeutics (in press).

 

BOOK CHAPTERS

 

 

1.                  Prentice CRM, Lowe GDO, Belch, JJF, Forbes CD. The role of defibrinating agents in the treatment of vascular disorders. In: Vascular Occlusion, Tesi M, Dormandy JA (eds). 1981; 37: 399-404.

 

2.                  Lowe GDO, Belch, JJF, Meek DR, Campbell AF, Forbes CD, Prentice CRM. Subcutaneous ancrod in prevention of deep vein thrombosis after hip surgery. In: Superficial and Deep Venous Diseases of the Lower Limb. Minerva Medica, Italy 1984: 227-8.

 

3.                  Prentice CRM, Belch, JJF, Leiberman P, Pollock JG, Lowe GDO, Forbes CD. Prostacyclin in severe arterial disease. In: Prostacyclin, Clinical Trials, Gryglewski RJ, Szczeklik A, McGill JC (eds). Raven Press: New York 1985: 1-5.

 

4.                  Prentice CRM, Belch, JJF. Prostacyclin in Raynaud's syndrome. In: Prostacyclin, Clinical Trials, eds Gryglewski RJ, Szczeklik A, McGill JC (eds). Raven Press: New York 1985: 7-13.

 

5.                  Belch, JJF. Leukotrienes as mediators of inflammation. In: Recent Advances in Rheumatology, Moll JMH, Sturrock RD (eds). Churchill Livingstone, Edinburgh 1986; 4: 37-52.

 

6.                  Belch, JJF. The treatment of Raynaud's phenomenon. In: Advanced Medicine 21, Brown MJ (ed). Churchill Livingstone, Edinburgh 1986; 234-42.

 

7.                  Greer IA, Belch, JJF. Prostacyclin in pregnancy induced hypertension, Raynaud's phenomenon and haemolytic uraemic syndrome. In: Prostacyclin, Past, Present and Future: Current Clinical Concepts, Williams EB, (ed). Raven Press: New York 1986; 3: 37-45.

 

8.                  Belch, JJF. The role of eicosanoids in inflammation. In: Immunopathogenic Mechanisms of Arthritis, Goodacre J, Dick WC (eds). MTP Press Ltd: Lancs 1988: 26-50.

 

9.                  Belch, JJF. The white blood cell - a new cardiovascular risk factor? In: Coronary Risk Factors Revisited, Shepherd J (ed). Elsevier Science Publishers, London 1989: 51-5.

 

10.             Belch, JJF. Essential fatty acids and rheumatoid arthritis. In: Omega-6-Essential Fatty Acids in Clinical Medicine, Horrobin DF (ed). Wiley-Liss Inc: New York 1990: 223-8.

 

11.             Belch, JJF, Maple C. Evening primrose oil and the fish oils - effect in rheumatoid arthritis. In: Essential Fatty Acids and Eicosanoids, Sinclair A, Gibson R (eds). American Oil Chemists Society Press: Champaign 1993; 356-360.

 

 

 

 

12.             Belch JJF. Prostaglandins in Raynaud's phenomenon. In: Therapeutic Applications of Prostaglandins. Vane J, O'Grady J (eds). Edward Arnold: London 1993: 219-239.

 

13.             Belch JJF, Nimmo M. Clinical aspects of splenomegaly. In: Disorders of the Spleen. A. Cuschieri, C.D. Forbes (eds). Blackwell Scientific Publications, Oxford 1993: 79-86.

 

14.             Lau CS, Belch JJF. Chapter 3. Diseases of joints and bones. In: A Colour Atlas and Text of Clinical Medicine. Forbes CD, Jackson WF (eds). Mosby-Wolfe, London 1993: 121-160.

 

15.             Belch JJF, McCollum P. Pharmacotherapy of critical limb ischaemia. In: Spinal Cord Stimulation - An Innovative Method in the Treatment of Peripheral Vascular Disease. Horsch S, Clacys L (eds). Springer International, Chester 1994: 95-112.

 

16.             Belch, JJF. The investigation and management of Raynaud's phenomenon. In: Clinical Problems in Vascular Surgery, Galland RB, Clyne CAC (eds). Edward Arnold, London 1994: 137-149.

 

17.             Belch JJF. Chapter 47. White cells, free radicals and scavengers. In: Haemostasis and Thrombosis (3rd edition). Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Churchill Livingstone, Edinburgh 1994: 1089-1106.

 

18.             Belch JJF, Maple C. Raynaud's phenomenon. In: Connective Tissue Disease. Belch JJF, Zurier R (eds), Chapman and Hall, London 1995: 131-150.

 

19.             Belch JJF. Temperature related disorders. In: Textbook of Vascular Medicine. Tooke J, Lowe GDO (eds). Edward Arnold, London 1995: 329-352.

 

20.             Belch JJF. The use of iloprost in critical limb ischaemia and Raynaud's Phenomenon. In: Therapeutic Applications of Iloprost, Norgren L (ed). Cambridge Medical Publications, London 1995: 59-69.

 

21.             Belch JJF, Söhngen W. Peripheral arterial disease. In: Handbook of Phase 1 & 2 Clinical Drug Trials. Dollery C, O'Grady J (eds). CRC Press Inc, Florida 1997; 249-278.

 

22.             Belch JJF, Ho M. Vasospastic disorders. Connective tissue disease and vasculitis. In: A Companion to Specialist Surgical Practice Vol VI: Vascular & Endovascular Surgery. Beard JD, Gaines PA  (eds). WB Saunders & Company, London 1998: pp 201-224.

 

23.             Belch JJF, McLaren M. Stable prostacyclin analogues. In: Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. Verstraete M, Fuster V, Topol EJ (eds). Lippincott-Raven Publishers, Philadelphia 1998: pp 265-283.

 

24.             Belch JJF, Muir A. Vascular risk, prophylaxis of thrombo-embolism, and the vasculitides: The Physician’s Approach. In: Anaesthesia for Vascular Surgery. Bannister J, Wildsmith JAW (eds). Edward Arnold, London, 2000: 32-59.

 

25.             Belch JJF. Basic Science of Angioplasty and Restenosis: Cellular mechanisms and interventional pharmacotherapy. In: Textbook of Endovascular Procedures. Dyet JF (ed). WB Saunders Company, 2000 (Section 1): 3-14.

 

26.             Belch JJF. Medical management of intermittent claudication. In Vascular and Endovascular Opportunities. Greenhalgh R (ed). WB Saunders Company, 2000. Charing Cross Symposia.

 

27.             Belch JJF. Contribution to vasoactive drugs. In Therapeutic Drugs, 2nd Edition. Dollery CT (ed). Churchill Livingstone, Edinburgh (in press).

 

28.             Newton DJ, Khan F, Belch JJF. Thermography and laser Doppler imaging in rheumatology. Isenberg DA, Renton P (Eds). Oxford University Press (in press).

 

29.             Belch JJF, Ho M. Vasospastic disorders and vasculitis. In: A Companion to Specialist Surgical Practice: Vascular and Endovascular Surgery 2nd Ed. Beard JD, Gaines PA (Eds). WB Saunders and Co, London (in press).

 

30.             Wong KYK, Struthers AD, Belch JJF. Evidence of Oxidative Stress in Heart Failure. In: Oxidative Stress and Cardiac Failure. Kukin ML, Fuster V (Eds). Futura Publishers, New York, 97-107.

 

31.             Al-Allaf AW, Belch JJF. Takayasu’s Arteritis: Indications for Surgery and Appropriate Procedures. In: Update in Vascular Surgery. Fiorino G (Ed). Foxwell & Davies Limited Scientific Publishers, London: 45-54.

 

32.             Al-Allaf AW, Belch JJF. Raynaud’s Phenomenon. In: Rheumatology 3C. Eds Hochberg, Silman AJ, Weinblatt, Weisman. Elsevier Science, London (in press).

 

33.             Newton DJ, Khan F, Belch JJF. Thermography and laser Doppler imaging in rheumatology. In: Imaging in Rheumatology. Eds D A Isenberg, P Renton. Oxford University Press 2002; 90-102.

 

34.             Belch JJF, Brophy C. Medical Management of Peripheral Arterial Disease. In: Vascular Surgery. Eds A Davies, C Brophy.  Springer Verlag (London) Limited. In press

 

 

REPORTS IN BOOKS

 

 

1.                  Belch, JJF, Walker J, McLaren M, Calder A, Forbes CD, Prentice CRM. Platelets in pregnancy induced hypertension. In: Prostacyclin in Pregnancy, Lewis PJ, Moncada S, O'Grady J (eds). 1983; 207-10.

 

2.                  McLaren M, Belch JJF, Forbes CD, Prentice CRM. Development of a radioimmunoassay for the measurement of prostacyclin metabolites in unextracted plasma. In Advances in Prostaglandin Thromboxane & Leukotriene Research 1985; 13: 41-42.

 

3.                  Belch JJF, McLaren M, Anderson J, Lowe GD, Sturrock RD, Capell HA, Forbes CD, Mikhailidis DP, Jeremy JY, Dandona P. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud’s syndrome. In Prostaglandins, Leukotrienes & Medicine 1985; 18 (3): 401-402.

 

4.                  Belch, JJF, Chopra M, Sturrock RD, Smith WE. Leukotriene B4 and its action within a free-radical generating system. In: Inflammatory Mediators, Higgs GA, Williams TJ (eds). MacMillan Press: London 1986: 240-1.

 

5.                  Shapiro D, Belch, JJF, Sturrock RD, Shenkin A. Effects of drugs altering arachidonic acid metabolism on interleukin-1 release from monocyte-like cells. In: Marker Proteins in Inflammation Volume 3, de Gruyter & Co: Berlin 1986: 43-5.

 

6.                  Belch, JJF, Shapiro D, Shenkin A, Sturrock RD. Prostacyclin production from vascular endothelium is enhanced by interleukin. In: Marker Proteins in Inflammation, Volume 3, de Gryter and Co: Berlin 1986: 41-2.

 

7.                  Belch, JJF, Ansell D, Saniabadi A, Forbes CD, Sturrock RD. Transdermally applied iloprost (ZK36-374) decreases whole blood platelet aggregation. In: Prostaglandins in Clinical and Biological Research, Sinzinger H, Schror K (eds). Liss Inc: New York 1987: 242: 413-7.

 

8.                  Belch, JJF, Chopra M, Tweddel A, Hutton I, Cobbe S, Smith E. Changes of redox status in blood of patients with acute myocardial infarction. In: Free Radicals: Recent Development in Lipid Chemistry, Experimental Pathology and Medicine, Dormandy T, Rice-Evans C (eds). Richelieur Press, Paris 1988: 321-2.

 

9.                  Belch, JJF, McLaren M, Chopra M, O'Dowd A, Forbes CD. Coagulation and haemorheological abnormalities in patients with vibration white finger. In: The Assessment and Associated Problems of Vibration White Finger (VWF), Aw TC, Cooke RA, Harrington JM, Krishnan G, Tyler LE (eds). University of Sheffield Press: Sheffield 1989: 18-28.

 

10.             Belch, JJF, Lau CS, Shaw W, McLaren M. Oxygen free radical generation following angioplasty for peripheral arterial disease. In: La Chiruriga Vascolare nella Comunita Economica Europea, Palombo D, Brustia P (eds). Domenico Palombo: Valle D'Aosta 1991: 127-8.

 

11.             Lui Y, Tweedie RJ, Abel EW, Belch JJF. Determination of cell electrical  characteristics by an impulse response technique. In: Proceedings XIV International Conference of the Engineering in Medicine and Biology Society.  Morucci JP, Plonsey P, Coatrieux JL, Laxminarayan S.  Institute of Electrical and Electronic Engineers Inc. 1992: 2709-2710.

 

12.             Taylor JE, Belch JJF, Henderson IS, Stewart WK. Erythropoietin does not increase whole-blood platelet aggregation in vitro. Nephrology, Dialysis, Transplantation 1993; 8 (11): 1291-1293.

 

13.             Koop A, Abel EW, Lui Y, Belch JJF. A pulse analysis technique for measurement of platelet cell volume. Proceedings 10th International Conference on Biomedical Engineering. Goh JCH, Nather A (eds). Biomedical Engineering Society of Singapore. ISBN 9971-62-374-9. 1994: 279-300.

 

14.             Lui Y, Abel EW, Belch JJF, Seunarine V, Wozencroft M. An IBM based Pulse Width Height Analyzer and its application in determination of leukocyte aggregation. Proceedings 10th International Conference on Biomedical Engineering. Goh JCH, Nather A (eds). Biomedical Engineering Society of Singapore. ISBN 9971-62-374-9. 1994: 121-123.

 

15.             Hickman P, Harrison DK, Hill A, McLaren M, Tamei H, McCollum PT, Belch JJF. Exercise in patients with intermittent claudication results in the generation of oxygen derived free radicals and endothelial damage. In: Oxygen Transport to Tissue XVI. Advances in Experimental Medicine & Biology Vol. 361. Hogan MC, Mathien-Costello O, Poole DC, Wagner PD (eds). Plenum Press, New York 1994; 361: 565-571.

 

16.             Hickman P, Harrison DK, Evan SD, Belch JJF, McCollum PT. Use of light guide reflectance spectrophotometry in the assessment of peripheral arterial disease. In: Oxygen Transport to Tissue XV . Vaupel P (ed). Advances in Medicine and Biology 1994; 345: 885-892.

 

17.             Belch JJF, Hickman P. Leucocyte activation & toxic oxygen metabolites/free radicals. In: Oxygen Transport to Tissue XIX. Harrison D, Delpy D (eds). Plenum Press 1997:1-5.

 

18.             Newton DJ, Harrison DK, Hanna GB, Thompson CJA, Belch JJF, McCollum PT. Microvascular blood flow and oxygen supply in ulcerated skin of the lower limb. In: Oxygen Transport to Tissue XIX. Harrison D, Delpy D (eds). Plenum Press 1997: 21-27.

 

19.             Khan F, Litchfield SJ, Belch JJF. Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral vascular disease and hypercholesterolaemia. In: Oxygen Transport to Tissue XIX. Harrison D, Delpy D (eds). Plenum Press 1997: 49-54.

 

20.             Elhadd TA, Jung RT, Newton RW, Stonebridge PA, Belch JJF. Incidence of asymptomatic peripheral occlusive disease in diabetic patients attending a  hospital clinic. In: Oxygen Transport to Tissue XIX. Harrison D, Delpy D (eds). Plenum Press 1997; 428: 45-48.

 

21.             Belch JJF. Intra-arterial injection after drug abuse: a cause of arterial trauma and potential for treatment with iloprost. In: Therapeutic Applications of Iloprost: Perspectives for the New Millennium. Kapp JF (Ed). Parthenon Medical Communications, Lancaster 2000; 32.

 

22.             Belch JJF. Therapy of Raynaud’s phenomenon and vasculitis. In: Therapeutic Applications of Iloprost: Perspectives for the New Millennium. Kapp JF (Ed). Parthenon Medical Communications, Lancaster 2000; 42-43.

 

BOOKS

 

 

1.         Belch JJF, McCollum P, Stonebridge PA, Walker W. A Colour Atlas of Vascular Disease, Mosby-Wolfe, London 1996.

 

2.         Belch JJF, Zurier R.  Connective Tissue Diseases. Chapman and Hall, London 1995.

 

WORK SUBMITTED FOR PUBLICATION

 

 

1.                  Taylor JE, McLaren M, Belch JJF. Effect of recombinant human erythropoietin therapy on blood coagulation and fibrinolysis in haemodialysis patients with multiple myeloma.

 

2.                  Craig EA, McLaren M, Jennings PE, MacEwen CJ, Belch JJF. Haemorheological effects of Argon laser photocoagulation in diabetic retinopathy.

 

3.                  Maple C, Bancroft A, McLaren M, Belch JJF. Tenidap sodium inhibits white blood cell aggregation in patients with rheumatoid arthritis: An in-vitro study.

 

4.                  Taylor JE, Belch JJF, McLaren M, Stewart WK. The effects of low-dose aspirin (Enteric coated 75mgs) on platelet aggregation in haemodialysis patients receiving erythropoietin.

 

5.                  Maple C, Kirk G, McLaren M, Belch JJF. Increased circulating E-Selectin following essential fatty acid supplementation in normal volunteers.

 

6.                  Wallis CB, McDiarmid AJ, Williams DR, Belch JJF. Does propofol affect platelet function?

 

7.                  Kirk G, Elhadd TA, McLaren M, Greene SA, Belch JJF. The effects of dietary essential fatty acid supplementation on soluble E-selectin levels in young patients with Type I diabetes mellitus.

 

8.                  Cariou R, Peeters PAM, Forbes CD, Lowe GDO, Belch JJF, Shaw B, Rumley A, Neccian J, Dickenson JP.  Clopidogrel compatibility with cardiac co-medication:  studies of interactions with a Beta-blocker, a calcium uptake antagonist and a cardiac glycoside.

 

9.                  Gillespie ND, Bonnar C, McLaren M, Pringle S, Belch JJF. Von Willebrand factor antigen is predictive of left ventricular function in the first 10 days following myocardial infarction.

 

10.             Kennedy G, McLaren M, Khan F, Belch JJF. Oral L-arginine supplementation has no effect on soluble levels of cell adhesion molecules or markers of endothelial function in patients with Raynaud's phenomenon.

 

11.             Ho M, Maple C, Raederstoff D, Morley K, Belch JJF. The effects of borage oil supplementation on non-steroidal anti-inflammatory drug requirements in patients with rheumatoid arthritis: A double blind placebo controlled study.

 

12.             Davidson DLW, McLaren M, Hanslip, Belch JJF. Thrombotic mechanisms in mild asymptomatic carotid disease and after stroke.

 

13.             Veale DJ, Nicoll AE, Nimmo M, Stonebridge PA, Belch JJF.Thrombolytic therapy in the management of critical limb ischaemia: A Dundee perspective.

 

14.             Farquharson CAJ, Butler R, Hill A, Belch JJF, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation.

 

15.             Belch JJF, Black CM. Akesson A, Smit AJ, Knobler R, Bruhlmann P, Wollersheim H, Ullman S, Madhok R, Banga J-D, Watson HR. Placebo-controlled trial of low dose oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis.

 

16.             Belch JJF, McEwan J, McLaren M, Allen MJ. The effects of Sildenafil on platelet aggregation.

 

17.             Newton DJ, Khan F, Belch JJF, Mitchell MR, Leese GP. Improvement of wound blood flow in diabetic foot ulcers treated with Dermagraft® - a novel skin replacement therapy.

 

18.             Newton DJ, Leese GP, Harrison DK, McCollum PT, Belch JJF. Cutaneous oxygen transport in diabetic foot ulcers.

 

19.             McEwan SR, Dewhurst NG, Daly F, Forbes CD, Belch JJF. Results of a survey of cardiovascular risk factor prevalence amongst health care workers.

 

20.             McEwan SR, Daly F, Forbes CD, Hawthorne VM, Belch JJF. The Scottish Heart and Arterial Risk Prevention (SHARP) survey of cardiovascular risk: regional differences.

 

21.             McEwan SR, Daly F, Forbes CD, Hawthorne VM, Belch JJF. A validation of the Scottish Heart and Arterial Risk Prevention (SHARP) cardiovascular risk score.

 

22.             Elhadd TA, Neary R, Abdu TAM, Kennedy G, Hill A, McLaren M, Akber M, Belch JJF, Clayton RN. Influence of the hormonal changes during the normal menstrual cycle in healthy young women on soluble adhesion molecules, plasma homocystein, free radical markers and lipoprotein fractions.

 

23.             Sun J, Abel EW, Bancroft A, Al-Allaf W, Belch JJF. Whole blood white cell and platelet aggregation in rheumatoid arthritis and drug treatment effect.

 

24.             Ho M, McLaren M, Daly F, Eastmond C, Nuki G, Belch JJF. Oxidised low density lipoprotein and homocysteinaemia are risk factors for macrovascular disease in systemic sclerosis.

 

25.             Young V, Ho M, Vosper H, Belch JJF, Palmer CNA. Transcriptional profiling of leukocytes in patients with systemic sclerosis using fluorescence-based real-time RT-PCR reveals biomarkers for the prediction of carotid artery disease.

 

26.             Ho M, Struthers A, Kennedy G, Nuki G, Eastmond C, Belch JJF. QT interval and vascular disease in systemic sclerosis.

 

27.             McLaren M, Belch JJF. Flow cytometric analysis of vascular endothelial growth factor expression by human monocyte, neutrophils and platelets.

 

28.             Dempsey OJ, Fowler S, Wilson A, Lipworth BJ, Belch JJF. Effects of adding either a leukotriene receptor antagonist or theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma.

 

29.             Kennedy G, Spence V, Underwood C, Belch JJF. Increased Neutrophil Apoptosis in Chronic Fatigue Syndrome.

 

30.             Barouni IM, Rowley D, McLaren M, Belch JJF. Blood parameters as potential non-invasive methods to diagnose deep venous thrombosis in total hip and knee replacement.

 

31.             Ho M, Maple C, Raederstoff D, Morley K, Belch JJF. The effects of borage oil supplementation on non-steroidal anti-inflammatory drug requirements in patients with rheumatoid arthritis – a double blind placebo controlled study.

 

32.             Malik R, Black DA, Muir A, Naidu S, Belch JJF, Cuschieri A. Case Report: Porto-mesenteric venous thrombosis associated with protein S deficiency and anitcardiolipin antibody.

 

33.             Innes AJ, Kennedy G, McLaren M, Bancroft A, Belch JJF. Dark chocolate inhibits platelet aggregation in healthy volunteers.

 

34.             Green FC, Levison R, Imrie M, Stonebridge PA, Belch JJF. Diabetes and impaired glucose tolerance in patients with atherosclerotic peripheral arterial disease:  Is it being missed?

 

35.             Houston JG, Gandy SJ, Dick JBC, Belch JJF, Stonebridge PA. Relationship of aortic arch spiral blood flow to the presence of carotid atheromatous disease: MRI and computational fluid dynamics modelling.

 

36.             Shehab AMA, MacFadyen RJ, McLaren M, Tavendale R, Belch JJF, Struthers AD. Sudden unexpected death in heart failure may be preceded by short term, intra-individual increases in inflammation and in autonomic dysfunction:  a pilot study

 

37.             Kennedy G, Spence V, Khan F, Belch JJF. Prolonged action of acetylcholine induced vasodilatation in blood vessels of patients with Chronic Fatigue Syndrome

 

38.             Belch JJF, MacKay IR, McKay A, Salenius J, Harper DR, Ostergren J, Ruckley CV, Lepäntalo M, Fagrell B, Engeset J, Söhngen M, Söhngen W. The Scottish-Finnish-Swedish PARTNER Study of Taprostene versus placebo treatment in patients with critical limb ischaemia.

 

39.             Khan F, Kennedy G, Spence VA, Newton DJ, Belch JJF. Peripheral cholinergic function in subjects with Chronic Fatigue Syndrome, Gulf War Syndrome, and with illness following organophosphate exposure.

 

40.             Cassar K, Belch JJF, Brittenden J. Management of vascular risk factors in patients with intermittent claudication by vascular surgeons.

 

41.             Treatment of Intermittent Claudication in Patients with Peripheral Arterial Disease by AT-1015, a Novel 5-Hydroxytryptamine Antagonist: The UK Experience.

 

42.             Belch JJFB, Baird RN, Robb R, McGrath C, Stewart AHR, Underwood CL. Vasogen immune modulation therapy increases walking distance in patients with intermittent claudication.

 

43.             The POPADAD Study Group. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) Trial design, methodology and recruitment.

 

44.             Stonebridge P, Buckley C, Thompson A, Houston JG, Dick J, Hunter G, Chudek JA, Belch JJF. Induced non-spiral and spiral (helical) flow patterns in stenoses: “In vitro” observations using spin and gradient echo magnetic resonance imaging (MRI) and computational fluid dynamic modelling.

 

45.             Elhadd TA, Kennedy G, Robb R, McLaren M, Jung RT, Belch JJF. Elevated soluble cell adhesion molecules E-selectin & Intercellular Cell Adhesion Molecule-1 in Type-2 diabetic patients with & without asymptomatic peripheral arterial disease.

 

46.             Raza Z, Belch JJF, McLaren M, McCollum PT. Lower limb amputation results in an improvement in endothelial function in the patient with advanced peripheral vascular disease.

 

 

 

 

LAY PUBLICATIONS AND PATIENT EDUCATION

 

 

 1.        Treatment of Raynaud's phenomenon (Chapter) 1986.

 

 2.        Systemic sclerosis (Booklet) 1986.

 

 3.        Raynaud's phenomenon (Booklet) 1986.

 

 4.        Raynaud's phenomenon (Video) 1987.

 

 5.        Blood stickiness and Raynaud's (Raynaud’s Association Newsletter) 1989.

 

 6.        Vibration white finger syndrome (Booklet) 1990.

 

 7.        Vibration white finger syndrome (with Dr. C. Lau). Raynaud's Association Newsletter 1991.

 

 8.        Erythromelalgia (with Dr. S. Wilson). Raynaud's Association Newsletter 1991.

 

 9.        Erythromelalgia (Booklet) 1988, 2nd Edition, 1992.

 

10.       The gullet and systemic sclerosis (with Mr S. Shimi). Raynaud's Association Newsletter, 1992.

 

11.       Vascular endothelium (with Dr. F. Khan). Raynaud's & Scleroderma Association Newsletter, 1993.

 

12.       Adhesion molecules (with Miss G. Kirk). Raynaud’s & Scleroderma Association Newsletter 1994.

 

13.       Erythromelalgia revisited (with Mrs. R. Littleford). Raynaud’s & Scleroderma Association Newsletter 1994.

 

14.       Reflex sympathetic dystrophy. Raynaud’s & Scleroderma Association Newsletter 1995.

 

15.       Beurger’s disease (Thromboangiitis Obliterans). Raynaud’s & Scleroderma Association Newsletter 1996.

 

16.       Advances in Raynaud's treatment:  The last 15 years.  Raynauds & Scleroderma Association Newsletter 1997.

 

17.       Iloprost information for patients & health professionals (Booklet) 1998.

 

18.       Quarterly ‘Doc Spot’ in Raynaud’s & Scleroderma Association Newsletter (1999-current).